Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid changes after 10-week induction therapy in inflammatory bowel disease
NL-OMON22770Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of corticosteroids, methotrexate, vedolizumab, ustekinumab and tofacitinib in inflammatory bowel disease (IBD) (7 cohorts), sponsored by Erasmus MC. Primary endpoint: Lipid changes after induction therapy. Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON22770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22770.